Demographics
| Overall | Arm 1 | Arm 2 | Arm 3 | Arm 4 | |
| Number | 66 | 13 | 13 | 20 | 20 |
| Age (years) | |||||
| Median | 70 | 67 | 73 | 71 | 66 |
| Range | 47–86 | 60–82 | 54–83 | 47–77 | 50–86 |
| Race/ethnicity, n (%) | |||||
| White (non-Hispanic) | 63 (95%) | 12 (92%) | 12 (92%) | 20 (100%) | 19 (95%) |
| White (unknown ethnicity) | 2 (3%) | 1 (8%) | 1 (8%) | 0 (0%) | 0 (0%) |
| Black or African-American | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5%) |
| Prior treatments, n (%) | |||||
| Bicalutamide | 58 (88%) | 13 (100%) | 12 (92%) | 17 (85%) | 16 (80%) |
| Any second-generation AR-targeted agent | 27 (41%) | 4 (31%) | 8 (62%) | 5 (25%) | 10 (50%) |
| Enzalutamide | 18 (27%) | 3 (23%) | 6 (46%) | 3 (15%) | 6 (30%) |
| Abiraterone | 12 (18%) | 1 (8%) | 2 (15%) | 2 (10%) | 7 (35%) |
| TAK-700/apalutamide | 4 (6%) | 2 (15%) | 1 (8%) | 1 (5%) | 0 (0%) |
| Taxane (docetaxel and/or cabazitaxel) | 18 (27%) | 2 (15%) | 3 (23%) | 4 (20%) | 9 (45%) |
| Radium 223 | 3 (5%) | 1 (8%) | 0 (0%) | 1 (5%) | 1 (5%) |
| Sipuleucel-T | 1 (2%) | 0 (0%) | 0 (0%) | 1 (5%) | 0 (0%) |
| Metastatic disease sites, n (%) | |||||
| Bone | 55 (83%) | 13 (100%) | 13 (100%) | 13 (65%) | 16 (80%) |
| Lymph node | 25 (38%) | 4 (31%) | 4 (31%) | 9 (45%) | 8 (40%) |
| Visceral | 7 (11%) | 1 (8%) | 2 (15%) | 3 (15%) | 1 (5%) |
| Baseline PSA (ng/mL) | |||||
| Median | 37.1 | 34.4 | 31.8 | 26.3 | 25.7 |
| Range | 2.6–811 | 3.1–173 | 5.8–245 | 7.3–356 | 2.6–811 |